Patents by Inventor Kanetada Shimizu

Kanetada Shimizu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230218686
    Abstract: A cognitive function-improving agent containing one or both of Bifidobacterium breve FERM BP-11175 and a culture of Bifidobacterium breve FERM BP-11175 as an active ingredient for administration to a subject who has not developed dementia is provided.
    Type: Application
    Filed: April 21, 2021
    Publication date: July 13, 2023
    Applicant: MORINAGA MILK INDUSTRY CO., LTD.
    Inventors: Kanetada Shimizu, Noriko Katsumata, Kazuya Ono
  • Publication number: 20230066928
    Abstract: Novel Bifidobacterium bacteria having an opioid peptide decomposition action and a noncollagenous glycoprotein decomposition action are provided. The present invention relates to one or more kinds of Bifidobacterium bacteria selected from the group consisting of Bifidobacterium bifidum MCC1092 (NITE BP-02429), Bifidobacterium bifidum MCC1319 (NITE BP-02431), Bifidobacterium bifidum MCC1868 (NITE BP-02432), Bifidobacterium bifidum MCC1870 (NITE BP-02433), and Bifidobacterium longum subsp. longum MCC1110 (NITE BP-02430), as well as a composition for decomposing an opioid peptide and composition for decomposing a noncollagenous glycoprotein containing the Bifidobacterium bacteria as an active ingredient.
    Type: Application
    Filed: October 18, 2022
    Publication date: March 2, 2023
    Applicant: MORINAGA MILK INDUSTRY CO., LTD.
    Inventors: Takuma Sakurai, Nanami Hashikura, Kanetada Shimizu, Sachiko Takahashi, Ayako Horigome
  • Patent number: 11504407
    Abstract: Novel Bifidobacterium bacteria having an opioid peptide decomposition action and a noncollagenous glycoprotein decomposition action are provided. The present invention relates to one or more kinds of Bifidobacterium bacteria selected from the group consisting of Bifidobacterium bifidum MCC1092 (NITE BP-02429), Bifidobacterium bifidum MCC1319 (NITE BP-02431), Bifidobacterium bifidum MCC1868 (NITE BP-02432), Bifidobacterium bifidum MCC1870 (NITE BP-02433), and Bifidobacterium longum subsp. longum MCC1110 (NITE BP-02430), as well as a composition for decomposing an opioid peptide and composition for decomposing a noncollagenous glycoprotein containing the Bifidobacterium bacteria as an active ingredient.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: November 22, 2022
    Assignee: MORINAGA MILK INDUSTRY CO., LTD.
    Inventors: Takuma Sakurai, Nanami Hashikura, Kanetada Shimizu, Sachiko Takahashi, Ayako Horigome
  • Patent number: 11400122
    Abstract: An object of the present invention is to provide an agent for improving a mental health disfunction or a composition for improving a mental health disfunction, and a food or drink composition for improving a mental health disfunction which are effective for improving a mental health disfunction, which are highly safe, and which can be continuously ingested on a daily basis, and this object is achieved by an agent for improving a mental health disfunction or a composition for improving a mental health disfunction, or a food or drink composition for improving a mental health disfunction, each comprising as an active ingredient a bacterium belonging to Bifidobacterium longum subsp. infantis.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: August 2, 2022
    Assignee: MORINAGA MILK INDUSTRY CO., LTD.
    Inventors: Hirosuke Sugahara, Kanetada Shimizu, Toshitaka Odamaki, Yeong Yeh Lee
  • Publication number: 20220133665
    Abstract: The object is to provide a method for inducing pili formation in bacterium of genus Bifidobacterium and a method for promoting intestinal colonization of the bacterium. 3-Phenylpropionic acid and/or 3-(4-hydroxyphenyl)propionic acid are an active ingredient of a composition for inducing the pili formation in the bacterium of genus Bifidobacterium and a composition for promoting the intestinal colonization of the bacterium.
    Type: Application
    Filed: February 28, 2020
    Publication date: May 5, 2022
    Applicants: MORINAGA MILK INDUSTRY CO., LTD., NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, THE KITASATO INSTITUTE
    Inventors: Kanetada Shimizu, Ro Osawa, Keita Nishiyama, Nobuhiko Okada, Nobuhiro Koyama, Takao Mukai, Hiroshi Tomoda
  • Patent number: 11241463
    Abstract: A composition includes cells of Lactobacillus paracasei MCC1849 (NITE BP-01633). The composition is in the form of a pharmaceutical composition, a food, a drink, or a feed. The pharmaceutical composition can be used for treating an inflammatory disease, ulcer, food allergies, bronchial asthma, urticaria, pollinosis, anaphylactic shock or an opportunistic infection.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: February 8, 2022
    Assignee: Morinaga Milk Industry Co., Ltd.
    Inventors: Tomohiro Tanaka, Noriyuki Iwabuchi, Yohei Sato, Kanetada Shimizu, Toshitaka Odamaki
  • Publication number: 20210196768
    Abstract: A novel agent useful for improving brain function is provided. The active ingredient in this agent is a Bifidobacterium breve and/or a Bifidobacterium breve-containing cultured material is provided.
    Type: Application
    Filed: March 17, 2021
    Publication date: July 1, 2021
    Applicant: MORINAGA MILK INDUSTRY CO., LTD.
    Inventors: Yodai Kobayashi, Tetsuya Kuhara, Kanetada Shimizu, Takumi Sato
  • Patent number: 10980849
    Abstract: A novel agent useful for improving brain function is provided. The active ingredient in this agent is a Bifidobacterium breve and/or a Bifidobacterium breve-containing cultured material is provided.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: April 20, 2021
    Assignee: MORINAGA MILK INDUSTRY CO., LTD.
    Inventors: Yodai Kobayashi, Tetsuya Kuhara, Kanetada Shimizu, Takumi Sato
  • Publication number: 20210100853
    Abstract: An object of the present invention is to provide an agent for decomposing an opioid peptide or composition for decomposing an opioid peptide that does not restrict dietary habits, does not provide side reactions, even if it is daily used, and thus can be continuously used without any worries. The object is achieved by an agent for decomposing an opioid peptide or composition for decomposing an opioid peptide, pharmaceutical composition for decomposing an opioid peptide, or food or drink composition for decomposing an opioid peptide containing a Bifidobacterium bacterium, a culture of the bacterium, and/or a processed cell product of the bacterium as an active ingredient.
    Type: Application
    Filed: March 23, 2018
    Publication date: April 8, 2021
    Applicant: MORINAGA MILK INDUSTRY CO., LTD.
    Inventors: Takuma Sakurai, Nanami Hashikura, Kanetada Shimizu, Akio Yamada
  • Publication number: 20210100852
    Abstract: Novel Bifidobacterium bacteria having an opioid peptide decomposition action and a noncollagenous glycoprotein decomposition action are provided. The present invention relates to one or more kinds of Bifidobacterium bacteria selected from the group consisting of Bifidobacterium bifidum MCC1092 (NITE BP-02429), Bifidobacterium bifidum MCC1319 (NITE BP-02431), Bifidobacterium bifidum MCC1868 (NITE BP-02432), Bifidobacterium bifidum MCC1870 (NITE BP-02433), and Bifidobacterium longum subsp. longum MCC1110 (NITE BP-02430), as well as a composition for decomposing an opioid peptide and composition for decomposing a noncollagenous glycoprotein containing the Bifidobacterium bacteria as an active ingredient.
    Type: Application
    Filed: March 23, 2018
    Publication date: April 8, 2021
    Applicant: MORINAGA MILK INDUSTRY CO., LTD.
    Inventors: Takuma Sakurai, Nanami Hashikura, Kanetada Shimizu, Sachiko Takahashi, Ayako Horigome
  • Publication number: 20200237837
    Abstract: A composition includes cells of Lactobacillus paracasei MCC1849 (NITE BP-01633). The composition is in the form of a pharmaceutical composition, a food, a drink, or a feed. The pharmaceutical composition can be used for treating an inflammatory disease, ulcer, food allergies, bronchial asthma, urticaria, pollinosis, anaphylactic shock or an opportunistic infection.
    Type: Application
    Filed: April 14, 2020
    Publication date: July 30, 2020
    Inventors: Tomohiro TANAKA, Noriyuki IWABUCHI, Yohei SATO, Kanetada SHIMIZU, Toshitaka ODAMAKI
  • Publication number: 20200181654
    Abstract: A technique is provided for degrading a resveratrol glycoside, or degrading a resveratrol glycoside and an isoflavone glycoside, to promote the production of an aglycone(s), thereby enhancing the absorption thereof into a living body. A bacterium belonging to the genus Bifidobacterium is used as an active ingredient of an aglycone production promoter which is used for promoting the production of an aglycone(s) from a glycoside(s). The aglycone production promoter is incorporated into a pharmaceutical composition for preventing and/or treating a disease for which an aglycone(s) is/are effective, or into a food or beverage composition for producing an aglycone(s).
    Type: Application
    Filed: June 19, 2017
    Publication date: June 11, 2020
    Applicant: MORINAGA MILK INDUSTRY CO., LTD.
    Inventors: Ruiqing Yao, Kanetada Shimizu, Toshitaka Odamaki
  • Patent number: 10653730
    Abstract: A method for prophylaxis or treatment of a disease includes administering an an effective amount of an agent that contains cells of Lactobacillus paracasei MCC1849 (NITE BP-01633) to a subject in need of such prophylaxis or treatment. The disease can be one or more of an inflammatory disease, ulcer, food allergies, bronchial asthma, urticaria, pollinosis, anaphylactic shock or an opportunistic infection.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: May 19, 2020
    Assignee: MORINAGA MILK INDUSTRY CO., LTD.
    Inventors: Tomohiro Tanaka, Noriyuki Iwabuchi, Yohei Sato, Kanetada Shimizu, Toshitaka Odamaki
  • Publication number: 20200038460
    Abstract: An object of the present invention is to provide an agent for improving a mental health disfunction or a composition for improving a mental health disfunction, and a food or drink composition for improving a mental health disfunction which are effective for improving a mental health disfunction, which are highly safe, and which can be continuously ingested on a daily basis, and this object is achieved by an agent for improving a mental health disfunction or a composition for improving a mental health disfunction, or a food or drink composition for improving a mental health disfunction, each comprising as an active ingredient a bacterium belonging to Bifidobacterium longum subsp. infantis.
    Type: Application
    Filed: February 22, 2018
    Publication date: February 6, 2020
    Applicant: MORINAGA MILK INDUSTRY CO., LTD.
    Inventors: Hirosuke Sugahara, Kanetada Shimizu, Toshitaka Odamaki, Yeong Yeh Lee
  • Patent number: 10335441
    Abstract: Further enhancement in useful effects of Bifidobacteria. An oral composition comprising (A) Bifidobacterium breve MCC1274 (FERM BP-11175) and (B) at least one cruciferous vegetable selected from the group consisting of broccoli and cabbage.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: July 2, 2019
    Assignee: SUNSTAR INC.
    Inventors: Yasumitsu Shimizu, Kanetada Shimizu
  • Publication number: 20190083549
    Abstract: A novel agent useful for improving brain function is provided. The active ingredient in this agent is a Bifidobacterium breve and/or a Bifidobacterium breve-containing cultured material is provided.
    Type: Application
    Filed: November 28, 2018
    Publication date: March 21, 2019
    Applicant: MORINAGA MILK INDUSTRY CO., LTD.
    Inventors: Yodai Kobayashi, Tetsuya Kuhara, Kanetada Shimizu, Takumi Sato
  • Publication number: 20180353557
    Abstract: A method for prophylaxis or treatment of a disease includes administering an an effective amount of an agent that contains cells of Lactobacillus paracasei MCC1849 (NITE BP-01633) to a subject in need of such prophylaxis or treatment. The disease can be one or more of an inflammatory disease, ulcer, food allergies, bronchial asthma, urticaria, pollinosis, anaphylactic shock or an opportunistic infection.
    Type: Application
    Filed: August 20, 2018
    Publication date: December 13, 2018
    Inventors: Tomohiro TANAKA, Noriyuki IWABUCHI, Yohei SATO, Kanetada SHIMIZU, Toshitaka ODAMAKI
  • Patent number: 10064903
    Abstract: The Lactobacillus paracasei MCC1849 (NITE BP-01633) strain, which has a high IL-12 production-promoting action, is used as an ingredient of a drug, food or drink, or feed used for promotion of IL-12 production, immunostimulation, antivirus, or the like.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: September 4, 2018
    Assignee: Morinaga Milk Industry Co., Ltd.
    Inventors: Tomohiro Tanaka, Noriyuki Iwabuchi, Yohei Sato, Kanetada Shimizu, Toshitaka Odamaki
  • Publication number: 20170246225
    Abstract: Further enhancement in useful effects of Bifidobacteria. An oral composition comprising (A) Bifidobacterium breve MCC1274 (FERM BP-11175) and (B) at least one cruciferous vegetable selected from the group consisting of broccoli and cabbage.
    Type: Application
    Filed: August 26, 2015
    Publication date: August 31, 2017
    Applicant: SUNSTAR INC.
    Inventors: Yasumitsu SHIMIZU, Kanetada SHIMIZU
  • Publication number: 20170007650
    Abstract: The Lactobacillus paracasei MCC1849 (NITE BP-01633) strain, which has a high IL-12 production-promoting action, is used as an ingredient of a drug, food or drink, or feed used for promotion of IL-12 production, immunostimulation, antivirus, or the like.
    Type: Application
    Filed: September 9, 2016
    Publication date: January 12, 2017
    Inventors: Tomohiro Tanaka, Noriyuki Iwabuchi, Yohei Sato, Kanetada Shimizu, Toshitaka Odamaki